Primagen and OncoGenome link up on cancer tests:
This article was originally published in Clinica
Executive Summary
Dutch company Primagen is to design and develop multiple molecular cancer diagnostic tests for Liege, Belgian firm OncoGenome Sciences. Primagen will endeavour to design five genomics-based diagnostic tests that can detect cancer much earlier and more accurately than current tests, the Amsterdam firm says. The tests should also be able to predict and monitor response to therapy for optimal, more individualised treatment decisions. Commenting on the collaboration, OncoGenome's CEO Herman Spolders said: "We plan to start dedicated end-development of clinical diagnostic testing services and kits of the molecular tests designed by Primagen over a year, followed by clinical trials as the first activities in the FDA approval procedure." OncoGenome has recently completed a E12m ($12.8m) funding round (see Clinica No 1050, p 15).